PMC10097926_01
(A) Arterial phase of the liver-enhanced CT scan showing the tumor lesion in segments 5 and 6. (B) Portal venous phase of the liver-enhanced CT scan showing the tumor lesion in segments 5 and 6; the arrow points at the liver lesion. (C,D) HE staining of pathological diagnosis.
fsurg-10-1081326-g001.jpg
PMC10097926_01_fsurg-10-1081326-g001.jpg
F1
A computed tomography (CT) scan showed that liver tumors were located in segments 5 and 6 (Figures 1A,B). The pathologic result confirmed the hepatic lesion was primary middle differentiated HCC (Figures 1C,D).
(A) Arterial phase of the Liver-enhanced computed tomography (CT) showing the tumor lesion in the appendix, the arrow point at the appendix. (B) portal venous phase of the the Liver-enhanced computed tomography (CT) showing the tumor lesion in the appendix, the arrow point at the appendix. (C, D) The HE stain of pathological diagnosis. The black arrow point at tumor lesion. The red arrow point at the appendix.
fsurg-10-1081326-g002.jpg
PMC10097926_01_fsurg-10-1081326-g002.jpg
F2
AFP and DCP levels were found to be elevated slightly. After the enhanced CT scan, a tumor with a diameter of 2 cm was found to adhere to the tip of the appendix (Figures 2A,B). The pathologic diagnosis confirmed that the lesion adhered to the appendix was a metastatic HCC (Figures 2C,D).
(A,B) PWI of the MRI scan showing the typical metastatic tumor in the liver; the arrow points at the lesion. (C,D) After TACE combined with angiogenesis inhibitors and ICIs, the typical lesions of the liver were covered by iodized oil, which were shown in the CT scan.
fsurg-10-1081326-g003.jpg
PMC10097926_01_fsurg-10-1081326-g003.jpg
F3
The maximum diameter of the recurrent intrahepatic lesion was 2 cm (Figures 3A,B). After 4 months, the CT scan showed that the typical site of liver metastasis had been covered by iodized oil (Figures 3C,D).
(A) AFP level of this patient from the first detection of HCC to the last treatment. (B) Timeline of the treatment for this patient.
fsurg-10-1081326-g004.jpg
PMC10097926_01_fsurg-10-1081326-g004.jpg
F4
The AFP level was found to decrease to the normal range (Figure 4A). The timeline for this patient's treatment is summarized in Figure 4B.